Physician

Andrew R Pogozelski, M.D.

According to 2025 Medicare claims, Andrew Pogozelski, M.D. (NPI: 1215199898) practices advanced heart failure and transplant cardiology in the Pittsburgh, PA market, with the plurality of this provider's patient population coming from Westmoreland, PA. This provider's primary affiliated billing organization is ALLEGHENY CLINIC (NPI: 1598071243; TIN: 251838458) and primary practice location at 15146-3513. Pogozelski is affiliated with the Physician Partners of Western PA LLC (ACO ID: A3547), participating under the MSSP model.

Pogozelski's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,922 traditional Medicare patients, billed 6,341 HCPCS/CPT codes, and received $304,082 in Medicare payments. The top billing code was 99233 (Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes). Part D data shows 7,388 prescription claims across 806 beneficiaries totaling $16,284,971 in drug costs, led by Vyndamax (Tafamidis). 2023 DME data shows 21 claims. Open Payments data shows 96 records totaling $43,978. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $100,328 to $304,082. Similarly, Part D prescription costs have moved sharply higher in recent years, from $627,060 to $16,284,971. In contrast, DME billing represents a smaller volume and rose steadily, from $4,836 to $49,777.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	529	1,446	$100,328
2016	593	1,634	$112,434
2017	765	2,116	$130,118
2018	889	2,559	$149,759
2019	1,065	3,178	$189,315
2020	1,400	3,941	$194,890
2021	1,665	4,940	$234,759
2022	1,811	5,705	$259,649
2023	2,012	6,100	$267,924
2024	1,922	6,341	$304,082

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	129	624	$627,060
2016	239	1,810	$973,095
2017	373	2,664	$1,210,601
2018	462	3,445	$2,076,030
2019	515	4,004	$3,617,298
2020	513	4,524	$5,564,856
2021	586	5,191	$6,253,043
2022	638	5,615	$4,887,687
2023	688	6,191	$6,388,965
2024	806	7,388	$16,284,971

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	154	$179,083
2017	N/R	94	$3,234
2018	N/R	N/R	N/R
2019	N/R	37	$825
2020	N/R	24	$2,013
2021	N/R	57	$28,237
2022	N/R	44	$44,440
2023	N/R	21	$47,084
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	187	476	$93
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	303	328	$85
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	719	777	$69
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	292	1,293	$61
93010	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	1,214	2,031	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Vyndamax	Tafamidis	393	12,344	$9,288,041
Adempas	Riociguat	227	6,600	$3,025,414
Uptravi	Selexipag	66	1,972	$1,582,713
Eliquis	Apixaban	601	34,989	$651,301
Opsumit	Macitentan	43	1,269	$528,023

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	96	$43,978	Actelion Pharmaceuticals US, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Andrew R. Pogozelski, M.D.?

Tedicare shows public-source Medicare data for Andrew R. Pogozelski, M.D. (NPI 1215199898), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Andrew R. Pogozelski, M.D. have ACO affiliation data?

Andrew R. Pogozelski, M.D. is shown with ACO affiliation data for Physician Partners of Western PA LLC (MSSP, ACO ID A3547).

What billing organization is linked to Andrew R. Pogozelski, M.D.?

Andrew R. Pogozelski, M.D. is linked to ALLEGHENY CLINIC (billing NPI 1598071243) in the available physician profile data.

Does Andrew R. Pogozelski, M.D. have Open Payments data?

Andrew R. Pogozelski, M.D. has 96 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.